At week @ , pazopanib , with allowance for as-needed ranibizumab injections , was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA ( estimated BCVA gains of @-@ @ vs. @ vs. @ letters , respectively ) .